Latest News

 

Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that it has entered into a non-binding Memorandum of Understanding (“MoU”) under which Beximco Pharma may acquire a majority shareholding (85.22%) in Nuvista Pharma Limited, a leading pharma company in Bangladesh specialising in hormones and steroid drugs (the “Proposed Acquisition”).

Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has commenced the export of Olopatadine, an ophthalmic product for treating the symptoms of eye allergy, to Canada.

Beximco Pharmaceuticals Limited ("Beximco Pharma" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the creation of a joint venture ("JV") with BioCare Manufacturing (M) Sdn Bhd ("BioCare") based in Malaysia, as the Company's first overseas manufacturing collaboration.

Beximco Pharmaceuticals Limited (“Beximco Pharma” or “the Company”; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the creation of a joint venture (“JV”) with BioCare Manufacturing (M) Sdn Bhd (“BioCare”) based in Malaysia, as the Company’s first overseas manufacturing collaboration.

Beximco Pharma has received approval for its Metformin Hydrochloride extended-release tablets, 500 mg and 750 mg, from the U.S. Food and Drug Administration (US FDA) on 13th December 2016. These are generic equivalent of Bristol-Myers Squibb′s Glucophage XR tablets, 500 mg and 750 mg.

Sandoz and Beximco Pharmaceuticals Join the Medicines Patent Pool’s Growing Network of Generic Manufacturing Partners

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has received US Food and Drug Administration (FDA) approval for Sotalol Hydrochloride, a generic version of the cardiovascular drug Betapace, following submission of an Abbreviated New Drug Application (ANDA) in June 2014.

First Bangladeshi pharmaceutical company to launch pharmaceutical products in the US

Beximco Pharmaceuticals Limited (“BPL”, “Beximco Pharma” or “Company”; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has commenced the export of Carvedilol, a prescription drug for treating hypertension, to the US. This follows the product′s approval from the US Food and Drug Administration (“US FDA”) in November 2015 and is the first time a pharmaceutical product from Bangladesh has been launched in the US.

First time a Bangladeshi pharmaceutical company has launched pharmaceutical products in any gulf member country.

Beximco Pharmaceuticals Limited (“BPL”, “Beximco Pharma” or “Company”), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces that it has commenced the export of pharmaceuticals to Kuwait.  This marks the first time a Bangladeshi pharmaceutical company has launched pharmaceutical products in any Gulf member country under the Gulf Cooperation Council (GCC).

Beximco Pharmaceuticals Limited has become the first Bangladeshi pharmaceutical company to receive approval for a prescription drug to be manufactured in this country for export to the USA. The Company says it has been granted formal approval from the U.S. Food and Drug Administration (“U.S. FDA”), following an extensive review of the submitted dossier and its manufacturing processes. This approval allows the Company to manufacture a popular blood pressure drug Carvedilol in different strengths (3.125 mg, 6.25 mg, 12.5 mg, and 25 mg) at the Company′s Tongi facility which recently achieved GMP approval from the US regulatory authority.